Investigators have found that combined treatment with two cancer immunotherapy drugs -- one a novel immune modulator and one that focuses and activates the anti-tumor immune response -- significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.
from Top Health News -- ScienceDaily https://ift.tt/2GrJx5M
No comments:
Post a Comment